Showing results (541-550 of 831) with videos related to
Sort By:
Pageof 84
Cancer|August 27, 2004
Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodiesMaher Albitar, Kim-Anh Do, Marcella M Johnson, et al.British Journal of Haematology|November 10, 2009
Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR)Gheath Alatrash, Maher Albitar, Susan O'Brien, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patientsApostolia-Maria Tsimberidou, Hagop M Kantarjian, Sijin Wen, et al.Blood|December 16, 2010
Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutationsElias Jabbour, Jorge Cortes, Fabio P S Santos, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2005
Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromesJorge Cortes, Stefan Faderl, Elihu Estey, et al.The Lancet. Haematology|December 22, 2015
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trialsPreetesh Jain, Hagop Kantarjian, Mona Lisa Alattar, et al.British Journal of Haematology|June 16, 2016
Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trialDai Chihara, Hagop Kantarjian, Susan O'Brien, et al.Cancer|October 24, 2013
HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemiaPaolo Strati, Hagop Kantarjian, Deborah Thomas, et al.Cancer|December 12, 2003
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic dataHagop M Kantarjian, Susan O'Brien, Jorge Cortes, et al.British Journal of Haematology|February 13, 2003
Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemiaWilliam G Wierda, Marcella M Johnson, Kim-Anh Do, et al.Pageof 84